The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of safety and pharmacokinetics of A166, a novel selective inhibitor of human epidermal growth factor receptor-2 in Chinese patients with advanced solid tumors.
 
Yongheng Liu
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
 
Wei Lian
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
 
Xi Zhao
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
 
Wei Qi
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
 
Jian Xu
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
 
Liang Xiao
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
 
Yan Qing
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
 
Tongtong Xue
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Leadership - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
 
Jingyi Wang
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Leadership - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.